期刊文献+

miR-155反义寡核苷酸对乳腺癌HS578T细胞增殖和凋亡的影响 被引量:2

Effects of antisense oligonucleotide targeting miR-155 on the proliferation and apoptosis of HS578T cells
下载PDF
导出
摘要 目的:探讨微小RNA 155(microRNA-155,miR-155)反义寡核苷酸(antisense oligonucleotide,ASO)对乳腺癌细胞增殖和凋亡的影响。方法:设计合成全硫代磷酸化修饰的miR-155 ASO,通过LipofectamineTM2000(Invitrogen)转染于乳腺癌HS578T细胞。CCK-8法检测乳腺癌细胞转染后的增殖情况,流式细胞仪分析转染率并检测细胞凋亡情况。结果:流式细胞仪检测转染率达70.5%。CCK-8试验结果显示转染miR-155 ASO后,HS578T细胞存活数明显低于空白组和脂质体组。流式细胞仪检测显示转染miR-155ASO后,HS578T细胞凋亡数明显增加。结论:miR-155 ASO可抑制乳腺癌HS578T细胞增殖,并促进其凋亡。提示miR-155可能成为乳腺癌治疗的靶基因。 Objective To investigate the effects of antisense oligonucleotide (ASO) targeting miR-155 on the proliferation and apoptosis of HS578T cells. Methods Specific phosphorothioate antisense oligodeoxynucleotides targeting miR-155 was synthesized and then transfected into the breast cancer cells HS578T by Invitrogen's LipofectamineTM 2000. Cell counting kit-8 (CCK-8) assay was used to detect the proliferation of HS578T, transfection efficiency and cell apoptosis rate were detected by flow cytometry. Results Transfection efficiency detected by flow cytometry was 70.5%. CCK-8 assay showed that the viability of HS578T cells was reduced great]y after transfection with miR-155 ASO as compared with that in blank group or liposomes group. Transfection with miR-155 ASO could promote apoptosis greatly. Conclusions MiR-155 ASO could suppress the proliferation of HS578T and promote its apoptosis, which indicate that miR-155 may be a target gene for the treatment for breast carcinoma.
出处 《实用医学杂志》 CAS 北大核心 2011年第24期4361-4363,共3页 The Journal of Practical Medicine
基金 浙江省卫生厅项目(编号:2009B106) 温州市鹿城区科技局项目(编号:S080219)
关键词 乳腺肿瘤 HS578T细胞 MicroRNA-155 反义寡核苷酸 增殖 凋亡 Breast neoplasms HS578T cells MicroRNA- 155 Antisense oligonucleotide Proliferation Apoptosis
  • 相关文献

参考文献4

二级参考文献54

  • 1Iorio MV,Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 2005,65: 7065 -7070.
  • 2Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993,75 : 843-854.
  • 3Tam W, Dahlberg JE. MiR-155/BIC as an oncogenic microRNA. Genes Chromosomes Cancer, 2006,45:211-212.
  • 4Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol, 2005,207:243-249.
  • 5Kluiver J, Haralambicva E, de Jong D, et al. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosomes Cancer,2006,45 : 147-153.
  • 6Chen HC, Chen GH, Chen YH, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer,2009,100 : 1002-1011.
  • 7Jung M, Mollenkopf HJ, Grimm C, et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med ,2009,9 : 10-15.
  • 8Wang X, Tang S, Le SY, et al. Aberrant expression of oneogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One,2008,3 :e2557.
  • 9Nikiforova MN, Tseng GC, Steward D, et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab,2008 ,93:1600-1608.
  • 10Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell ,2006,9 : 189-198.

共引文献14

同被引文献42

  • 1Mimezami AH, Pickard K, Zhang L, et al. MicroRNAs: key players in carcinogenesis and novel therapeutic targets [J]. Eur J Surg Oncol, 2009, 35:339-347.
  • 2Yang L, Belaguli N, Berger DH. MicroRNA and colorectal cancer[J]. World J Surg, 2009, 33:638-646.
  • 3Aukerman MJ, Sakai H. Regulation of flowering time and floral organ identity by a MicroRNA and its APETALA2-1ike target genes [J]. Plant Cell, 2003, 15(11): 2730-2741.
  • 4Sen GL, Blau HM. Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies [J]. Nat Cell Biol, 2005, 7 (6): 633-636.
  • 5Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology,and paths to treatment [J]. Genes Dev, 2007, 21(21): 2683-2710.
  • 6Stummer W Pichlmeier U, Meinei T, et al. Fluorescence-guided surge- ry with5-am-inolevulinic acid for resection of malignant glioma:a randomised controlled multicentre phase III trail [J]. Lancet Oncol, 2006, 7(5): 359-360.
  • 7Sabbah P, Foehrenbaeh H, Dutertre G, et al. Multimodal anatomic, functional,and metabolic brain imaging for tumor resection [J]. Clin Imaging, 2002, 26(1): 6-12.
  • 8D A Reardon, A Desjardins, J J Vredenburgh, et al. Metronomic chemotherapy with daily,oral etoposide plus bevacizumab for recurre- nt malignant glioma: a phase II study [J]. Br J Cancer, 2009, 101 (12): 1986-1994.
  • 9Imperato JP, Paleologos NA, Vick NA, et al. Effects of treatment on long-term survivors with malignant astrocytomas [J]. Ann Neurol, 1996, 28(6): 818-822.
  • 10Lee SW, Fraass BA, Marsh LH, et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study [J]. Int J Radiat Oncol Biol Phys, 1999, 43(1): 79-88 M.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部